Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OZ1 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 001 | EXPERIMENTAL | OZ1 Single intravenous infusion of 2-20 x 10 to the power of 7 OZ1 transduced autologous CD34+ cells per kilogram of body weight |
| 002 | PLACEBO_COMPARATOR | Placebo Single intravenous infusion of placebo transduced autologous CD34+ cells per kilogram of body weight |
| Name | Type | Description |
|---|---|---|
| Placebo | OTHER | Single intravenous infusion of placebo. |
| OZ1 | GENETIC | Single intravenous infusion of OZ1. |
| CD34+ cells | GENETIC | Autologous CD34+ cells. |
Inclusion Criteria: * An Human Immunodeficiency Virus 1 (HIV-1) infection for at least 6 months documented by positive HIV serology including confirmation by Western Blot * Receiving either the first or second regimen of antiretroviral therapy (ART) defined as 3 or more antiretroviral drugs in comb...
OZ1 is an investigational gene therapy being studied for the treatment of HIV-1 infection. It is designed to be administered to patients with HIV-1, and it has been evaluated in a clinical trial for this condition. OZ1 is not approved and remains in clinical development.
OZ1 is a gene therapy that uses autologous CD34+ hematopoietic progenitor cells transduced with an anti-HIV-1 ribozyme. The ribozyme is designed to target HIV-1, with the goal of inhibiting viral replication. This mechanism is being studied in patients with HIV-1 infection.
OZ1 is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker JNJ. The therapy is currently in Phase 2 clinical development for the treatment of HIV-1 infection.
OZ1 is in Phase 2 clinical development. It is an investigational gene therapy for HIV-1 infection and has not been approved by regulatory authorities. One Phase 2 clinical trial of OZ1 has been completed.
OZ1 has been studied in one completed Phase 2 clinical trial, identified as NCT00074997. This trial evaluated the efficacy and safety of autologous CD34+ hematopoietic progenitor cells transduced with OZ1 in participants with HIV-1 infection. The trial was conducted in Australia.
OZ1 is a gene therapy that involves transducing autologous CD34+ hematopoietic progenitor cells with an anti-HIV-1 ribozyme. It is being studied as a potential treatment for HIV-1 infection and is currently in Phase 2 clinical development by Johnson & Johnson.